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Breast cancer is the most common neoplasia in women. Despite 
important advances in treatment, metastatic breast cancer is incur-
able and new treatments to improve patient outcome are needed. 
Therefore, identification of the key molecular alterations that 
induce proliferation or drug resistance in breast cancer cells will be 
helpful in defining potential therapeutic targets.
Tyrosine kinases, either cytosolic (soluble) or transmembrane 
(membrane-bound), play important roles in animal physiology, 
and their deregulation has been linked to the development and 
progression of different types of cancer (1,2). In breast cancer, 
overexpression of the HER2 (also known as v-erb-b2 erythro-
blastic leukemia viral oncogene homolog 2), a receptor tyrosine 
kinase (RTK) (2), occurs in approximately 25% of patients and is 
associated with shorter survival (3). These findings led to several 
preclinical studies that confirmed the oncogenic potential of 
HER2 (4–7) and also led to the development of therapeutic agents 
targeting HER2 (2). One of these compounds is trastuzumab—a 
humanized monoclonal antibody that binds to the extracellular 
domain of HER2 (8,9). In HER2-overexpressing breast tumors, 
treatment with trastuzumab in combination with other antineo-
plastic drugs increases patient survival in metastatic and early-stage 
breast cancer (10,11). Despite the effectiveness of such treatments, 
a substantial number of HER2-positive patients do not respond to 
trastuzumab or relapse in a short period of time (12). Therefore, 
the development of novel therapeutic strategies that are aimed at 
increasing the efficacy of trastuzumab may help in preventing or 
delaying relapse in patients with HER2-positive tumors (12). In 
this context, the combined targeting of HER2 and other tyrosine 
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 Background  The receptor tyrosine kinase, HER2, is overexpressed in approximately 25% of patients with breast cancer and 
is  implicated  in  the  aggressiveness  of  cancer.  Targeting  of  HER2  signaling  with  trastuzumab,  a monoclonal 
antibody that inhibits HER2 activity, has demonstrated clinical benefits.
  Methods  We investigated whether the antitumor activity of trastuzumab can be potentiated by dasatinib, a small-molecule 
tyrosine kinase inhibitor, on breast cancer cell lines that overexpress HER2 (BT474 and SKBR3) or have normal 
HER2  expression  (MCF7  and  T47D).  Functional,  biochemical,  and  gene  expression  microarray  studies  were 
performed to  test  the effect of  trastuzumab, dasatinib, or a combination of  trastuzumab and dasatinib on cell 
proliferation; HER activation;  cell  cycle; DNA damage;  and apoptosis.  The effect of  drugs on mice  (n =  6 per 
group) bearing xenograft tumors originating from HER2-overexpressing BT474 cells was assessed, and tumors 
were evaluated for an effect on volume, HER signaling, and DNA damage. All statistical tests were two-sided.
  Results  Trastuzumab and dasatinib combination showed a synergistic effect on the proliferation of HER2-overexpressing 
breast  cancer cells  (combination  index = 0.44, 95% confidence  interval = 0.30  to 0.58). The drug combination 
also  induced a stronger  inhibitory effect on HER2 activation  than  the  individual drugs, decreased  the  level of 
proteins involved in DNA damage response, induced DNA double-strand breaks, cell cycle arrest, and caspase-
independent apoptosis. Mice (n = 6 per group) bearing xenograft tumors originating from HER2-overexpressing 
BT474 cells showed statistically significantly reduced tumor volume on day 28 when treated with the drug com-
bination (control vs trastuzumab and dasatinib combination; mean volume = 2.6 vs 0.5 cm3, difference = 2.1 cm3, 
95%  confidence  interval  =  0.76  to  3.51  cm3, P  =  .01)  and  total  regression  of  tumors  by  day  36 with  no  later 
relapse.
 Conclusions  Results showed that HER2 and dasatinib-sensitive tyrosine kinases act in a synergistic manner to safeguard the 
breast cancer cells from DNA damage. The therapeutic targeting of multikinase inhibition opens new avenues 
for the treatment of HER2-positive breast cancer patients.
    J Natl Cancer Inst 2010;102:1432–1446
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0.1 µg/dot for dot blot, and 1:5000 dilution for immunoblot 
studies); mouse monoclonal IgG2b anti-phosphotyrosine (clone 
PY99, 1:10 000 dilution); rabbit polyclonal IgG anti–myeloid cell 
leukemia sequence 1 (MCL1) (raised against an epitope mapping 
within an internal region of human MCL1; 1:2000 dilution); rabbit 
polyclonal anti–baculoviral IAP repeat-containing 2 protein 
(BIRC2, also known as c-IAP-1 inhibitor of apoptosis protein 1) 
(raised against an epitope corresponding to amino acids 111–193 
mapping within an internal region of human BIRC2; 1:2000 dilu-
tion); mouse monoclonal anti–glyceraldehyde-3-phosphate dehy-
drogenase (1:10 000 dilution); rabbit polyclonal anti–nuclear 
apoptosis–inducing factor 1 (NAIF1, also known as AIF-1) (raised 
against an epitope corresponding to amino acids 1–300 mapping at 
the amino [N] terminus of human NAIF1; 1:2000 dilution); rabbit 
polyclonal anti-SRC antibody (raised against the N terminus of 
human SRC; 1:1000 dilution); rabbit polyclonal anti–protein tyro-
sine kinase-2 (PTK2, also known as focal adhesion kinase [FAK]) 
(raised against the C terminus of human FAK; 1:1000 dilution); 
mouse monoclonal anti–SRC homology 2 domain–containing 
transforming protein 1 (SHC1) (raised against an epitope corre-
sponding to amino acids 366–473 of human SHC1; 1:5000 dilution); 
goat polyclonal anti-AKT1 (raised against the C terminus of human 
AKT1; 1:1000 dilution); rabbit polyclonal anti–mitogen-activated 
protein kinase 1 (MAPK1, also known as ERK1) (raised against an 
epitope mapping to the C terminus of ERK2 of rat origin, cross 
kinases presents an interesting strategy because these tyrosine ki-
nases are associated with breast cancer tumorigenesis and are of 
substantial interest as potential drug targets (12). The insulinlike 
growth factor 1 receptor (IGF-1R), an RTK, has been shown to 
increase the growth of breast cancer cells and is also implicated in 
developing resistance to trastuzumab (13). Indeed, cotargeting of 
IGF-1R and HER2 offers an important advantage over targeting 
of the individual RTKs in breast cancer cells (14). The v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 
(c-KIT) RTK is overexpressed in triple-negative breast cancers 
(those that do not express estrogen receptor, progesterone re-
ceptor, and HER2) (15). The activation of two nonreceptor cyto-
solic tyrosine kinases, c-abl oncogene 1 (ABL1) and c-SRC 
tyrosine kinase (CSK), is associated with the aggressiveness of 
breast cancer (16) and proliferation of triple-negative breast can-
cers (16,17), respectively. Moreover, c-SRC has also been associ-
ated with antiestrogen resistance in estrogen receptor–positive 
breast tumors (18).
Dasatinib, a small-molecule tyrosine kinase inhibitor, has been 
shown to target the cytosolic c-SRC and ABL1 kinases, as well as 
the RTKs c-KIT and platelet-derived growth factor receptors 
alpha and beta (17,19–21). The reported biological activity of 
dasatinib against triple-negative breast cancer (17,20), together 
with its favorable antitumoral activity in head and neck cancer 
when combined with gefitinib (22), led us to explore whether 
dasatinib could increase the antitumoral effect of trastuzumab on 
HER2-positive breast cancers.
In this study, we investigated the effects of trastuzumab and 
dasatinib combination on HER2 activation and HER2-mediated 
signaling using biochemical and gene expression microarray 
analyses and determined the effectiveness of the drug combination 
in preclinical mouse models.
Materials and Methods
Reagents and Antibodies
Cell culture medium (Dulbecco’s modified Eagle medium 
[DMEM]) and serum (fetal bovine serum [FBS]) were purchased 
from Invitrogen (Gaithersburg, MD). Protein A-Sepharose was 
from GE Healthcare Life Sciences (Piscataway, NJ). Immobilon-P 
membranes were from Millipore Corporation (Bedford, MA). 
Nitrocellulose membranes were from Bio-Rad Laboratories 
(Hercules, CA). Trastuzumab and dasatinib were from Roche 
Diagnostics (Barcelona, Spain) and Bristol-Myers Squibb 
(Princeton, NJ), respectively. Other generic chemicals were pur-
chased from Sigma-Aldrich (St Louis, MO), Roche Biochemicals 
(Hoffmann, Germany), or Merck (Darmstadt, Germany). The 
caspase inhibitors (Z-IETD-FMK, Z-LEHD-FMK, and Z-VAD-
FMK) were obtained from BD Biosciences (San Jose, CA).
The following antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA)—rabbit polyclonal anti-HER3 
antibody (raised against the carboxyl [C] terminus of human 
HER3; 1 µg/mg of protein lysate for immunoprecipitation, 0.1 µg/
dot for dot blot, and 1:5000 dilution for immunoblot studies); 
mouse monoclonal IgG2a anti-HER4 (raised against an epitope 
mapping between amino acids 1280–1308 at the C terminus of 
human HER4; 1 µg/mg of protein lysate for immunoprecipitation, 
CONTEXT AND CAVEATS
Prior knowledge
Trastuzumab  is  a  humanized monoclonal  antibody  that  binds  to 
and  inhibits  the  activity  of  HER2,  a  receptor  tyrosine  kinase. 
Although trastuzumab in combination with other anticancer drugs 
can  increase  the  survival  of  patients  with  HER2-positive  breast 
cancer, some do not respond to trastuzumab treatment.
Study design
In  vitro  and  in  vivo models  of HER2-positive  breast  cancer were 
used to investigate if trastuzumab in combination with dasatinib, a 
tyrosine  kinase  inhibitor  reported  to  have  antigrowth  activity  in 
breast cancer cells, showed greater inhibition of breast cancer cell 
proliferation and tumor development.
Contribution
Trastuzumab  and  dasatinib  combination  showed  a  synergistic 
effect  on  the  inhibition  of  HER2-overexpressing  breast  cancer 
cell proliferation and a complete regression of tumor xenografts 
in  the  in  vivo  mouse  model  with  no  relapse  after  treatment 
discontinuation.
Implications
The antitumor activity of trastuzumab can be potentiated by dasat-
inib in HER2-positive tumors.
Limitations
The efficacy of the drug combination in a mouse model is not in-
dicative of clinical success. In addition, whether an effective dose 
of  the drug  combination has  an  adverse  effect  in humans  is  not 
known.
From the Editors
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reacts with both human ERK1 and ERK2; 1:10 000 dilution); 
mouse monoclonal IgG2a anti–cyclin-dependent kinase-2 (CDK2) 
(raised against human recombinant CDK2; 1:1000 dilution); rabbit 
polyclonal anti-cyclin E1 (CCNE1) (raised against the C terminus 
of human cyclin E1, also recognizes cyclin E2 [CCNE2]; 1:1000 
dilution); rabbit polyclonal anti-cyclin B1 (CCNB1) (raised against 
an epitope corresponding to amino acids 1–300 of human cyclin 
B1; 1:1000 dilution); rabbit polyclonal anti–cyclin-dependent 
kinase inhibitor 1A (CDKN1A, also known as p21) (raised against 
the C terminus of human p21; 1:5000 dilution); rabbit polyclonal 
anti–cyclin-dependent kinase inhibitor 1B (CDKN1B, also known 
as p27) (raised against the C terminus of human p27; 1:5000 dilu-
tion); rabbit polyclonal anti–excision repair cross-complementing 
rodent repair deficiency, complementation group 4 (ERCC4, also 
known as RAD1) (raised against an epitope corresponding to 
amino acids 1–282 of human RAD1; 1:1000 dilution); rabbit poly-
clonal anti-RAD51 (raised against an epitope corresponding to 
amino acids 1–92 of human RAD51; 1:1000 dilution); mouse 
monoclonal anti-RAD54B (clone 19-K2, raised against recombi-
nant RAD54B; 1:1000 dilution); rabbit polyclonal anti-RAD50 
(raised against an epitope corresponding to amino acids 1013–1312 
mapping to the C terminus of human RAD50; 1:1000 dilution); 
and goat polyclonal anti–meiotic recombination 11 homolog A 
(MRE11A) (raised against the C terminus of human MRE11A; 
1:5000 dilution).
The mouse monoclonal anti-HER2 antibody (clone Ab-3, recog-
nizes an epitope corresponding to amino acids 1242–1255 at the 
C terminus of human HER2; 1 µg/mg of protein lysate for immuno-
precipitation, 0.1 µg/dot for dot blot, and 1:10 000 dilution for im-
munoblotting) was purchased from Calbiochem (La Jolla, CA); 
cetuximab, the anti–epidermal growth factor receptor (EGFR) (also 
known as HER1) antibody (1 µg/mg of protein lysate for immuno-
precipitation and 0.1 µg/dot for dot blot), was purchased from Merck 
(Madrid, Spain). A polyclonal anti-EGFR antibody (raised against 
the amino acids 909–1210 of the C terminus of human EGFR, dilu-
tion 1:5000 for immunoblotting) was raised in our laboratory (23).
The following rabbit polyclonal antibodies were purchased from 
Cell Signalling Technology (Beverly, MA)—anti-phosphorylated 
(Tyr1248) HER2 (1:1000 dilution); anti–phosphorylated (Tyr416) 
SRC (1:1000 dilution); anti–phosphorylated (Tyr421/Ser424) 
ribosomal protein S6 kinase, 70 kDa, polypeptide 2 (RPS6KB2, 
also known as p70S6K) (1:5000 dilution); anti–phosphorylated 
(Ser136) BCL2-associated agonist of cell death (BAD) (1:1000 
dilution); and anti–phosphorylated (Ser139) H2A histone family, 
member X (H2AFX, also known as H2AX, and its phosphorylated 
form at this site is known as gH2AX) (1:1000 dilution). The rabbit 
monoclonal anti-BAD antibody (clone 11E3; 1:1000 dilution) and 
the mouse monoclonal anti–phosphorylated (Ser1981) ataxia 
telangiectasia mutated (clone 10H11.E12; 1:1000 dilution) were 
also purchased from Cell Signalling Technology.
The following antibodies were purchased from BD Biosciences—
the mouse monoclonal anti-caspase-3 (CASP3) (clone 19, raised 
against amino acids 1–219 of human caspase 3; 1:2000 dilution); 
mouse monoclonal anti-caspase-8 (CASP8) (clone 3-1-9, raised 
against full-length recombinant human caspase 8; 1:1000 dilution); 
mouse monoclonal anti-caspase-9 (CASP9) (clone 2-22, raised 
against amino acids 1–134 of human caspase-9; 1:1000 dilution); 
mouse monoclonal anti–B-cell CLL/lymphoma 2 (BCL2) (clone 
6C8, raised against human recombinant BCL2; 1:2000 dilution); 
rabbit polyclonal anti–BCL2-like 1 (BCL2L1, also known as BCL-
X) (raised against amino acids 18–233 of human BCL2L1; 1:5000 
dilution); and mouse monoclonal anti–phosphotyrosine-horserad-
ish peroxidase (HRP) (clone PY20; 1:1000 dilution).
The cyanine 3 (Cy-3)–conjugated secondary antibodies were 
from Jackson ImmunoResearch Laboratories, Inc (West Grove, PA); 
Alexa 488-conjugated antibody was from Invitrogen; HRP conju-
gates of anti-rabbit and anti-mouse IgG were from Bio-Rad 
Laboratories; rabbit polyclonal anti-calnexin antibody was from 
Stressgen Biotechnologies Corporation (Victoria, Canada); and anti–
phosphorylated human AKT (Serine 473) antibody was raised in our 
laboratory against the amino acid sequence RPHFPQFpS473YSAS 
(p = phosphorylated).
Cell Culture
Four breast cancer cell lines—BT474, SKBR3, MCF7, and 
T47D—were grown in DMEM supplemented with 10% FBS, 100 
mU/mL penicillin (Invitrogen), 100 µg/mL streptomycin 
(Invitrogen), and 2 mM l-glutamine (Invitrogen) in a 5% CO2 
atmosphere at 37°C. The cell lines were obtained from the American 
Type Culture Collection Cell Biology Collection (Manassas, VA). 
The BT474 and SKBR3 cell lines overexpress HER2 receptor, 
whereas MCF7 and T47D cell lines have normal HER2 expression 
(24). The level of HER2 proteins in these cell lines was verified by 
immunoblotting (Supplementary Figure 1, available online).
For three-dimensional cell culture, 12-mm coverslips were 
coated with 60 µL of ice-cold Matrigel (BD Biosciences) and incu-
bated at 37°C for 20 minutes to allow the Matrigel to solidify. 
Cells were treated for 5 minutes with 0.25% trypsin–EDTA solu-
tion (2.5 g/L of trypsin, 0.38 g/L of EDTA) (Invitrogen). A single-
cell suspension containing 5 × 103 cells per 100 µL volume of 
medium, supplemented with 2% (vol/vol) of Matrigel, was care-
fully placed on top of the solidified Matrigel. Incubation was car-
ried out at 37°C for 30 minutes to allow the cells to attach to the 
Matrigel. The coverslips were then placed in six-well plates, 500 
µL of medium was added per well, and the cells were cultured for 
10 days. Cells were then treated with different drugs (10 nM 
trastuzumab, 1 µM dasatinib, or a combination of 10 nM trastu-
zumab and 1 µM dasatinib) for 1 week. Selection of the combina-
tion dose of trastuzumab was based on previously reported data 
(14). Phase contrast photographs of cells as monolayers, or in 
three-dimensional cultures, were taken with a Nikon Eclipse Ti-S 
inverted microscope (Izasa, Barcelona, Spain). The microscope 
was equipped with a ProgRes C3 camera and the ProgRess 
CapturePro 2.7 software, purchased from Jenoptik (Jena, 
Germany). Quantitation of the sphere diameters was performed 
manually by tracing a straight line across the diameter of the 
sphere and scoring its value as arbitrary length units. Two hundred 
spheres were scored for each condition, and the mean and 95% 
confidence interval (CI) values were calculated.
Immunoprecipitation and Immunoblotting
BT474, SKBR3, MCF7, and T47D cells were grown in DMEM 
with 10% of FBS and at 80% confluence (2 days later) were treated 
with drugs (10 nM trastuzumab, 1 µM dasatinib, or a combination 
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of 10 nM trastuzumab and 1 µM dasatinib) for 48 hours. Cells were 
washed with phosphate-buffered saline (PBS) (137 mM NaCl, 
2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4) and lysed in ice-
cold lysis buffer (20 mM Tris–HCl [pH 7.0], 140 mM NaCl, 
50 mM EDTA, 10% glycerol, 1% Nonidet P-40, 1 µM pepstatin, 
1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 mM phenylmethyl sul-
fonyl fluoride, 1 mM sodium orthovanadate). Lysates were centri-
fuged at 10 000g at 4°C for 10 minutes, and supernatants were 
treated with the corresponding antibody and protein A-Sepharose. 
Immunoprecipitations were performed at 4°C for at least 2 hours; 
immune complexes were recovered by a short centrifugation at 
10 000g for 15 seconds, followed by three washes with 1 mL cold 
lysis buffer. Samples were then boiled in electrophoresis sample buffer 
and placed on 6%–15% sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) gels, depending on the molecular 
weight of the proteins to be analyzed. Immunoblotting was per-
formed as previously described (25). Briefly, after electrophore-
sis, proteins in gels were transferred to polyvinylidene difluoride 
membranes (Millipore Corporation). Membranes were blocked 
in Tris-buffered saline with Tween (TBST) (100 mM Tris 
[pH 7.5], 150 mM NaCl, 0.05% Tween 20) containing 1% of 
bovine serum albumin for 1 hour and then incubated with the 
corresponding antibody for 2–16 hours. After washing with 
TBST, membranes were incubated with HRP-conjugated anti-
mouse or anti-rabbit secondary antibodies (1:10 000 dilution) for 
30 minutes and bands were visualized by using ECL Plus 
Western Blotting Detection System (GE Healthcare, 
Buckinghamshire, United Kingdom).
Dot Blots and Antibody Arrays
For dot blots, each antibody (0.1 µg) was adsorbed onto a nitrocel-
lulose membrane. The membrane was dried at room temperature 
for 30 minutes and then blocked for 2 hours in TBST containing 
5% bovine serum albumin. The membranes were then incubated 
with 1 mg of protein lysates overnight at 4°C. The membranes 
were washed in TBST three times and incubated for 2 hours with 
the anti–phosphotyrosine-HRP antibody (1:5000 dilution). After 
three washes of 10 minutes each in TBST, membranes were incu-
bated with the ECL Plus Western Blotting Detection System. The 
BT474 cell lysates were used as the positive control, as they con-
tain high levels of resting tyrosine phosphorylation of several cel-
lular proteins (26).
To perform the dot blot analyses with commercial arrays, we 
used the human phospho-RTK array kit (R&D Systems, Abingdon, 
United Kingdom) and followed the manufacturer’s instructions.
Cell Surface Biotinylation and Cell Fractionation
For cell surface biotinylation, BT474 cells (2 × 106 cells per 100-
mm dishes) were cultured in DMEM supplemented with 10% 
FBS, until the cells reached 80% confluence. Cells were then 
treated with different drugs (10 nM trastuzumab, 1 µM dasatinib, 
or a combination of 10 nM trastuzumab and 1 µM dasatinib) for 48 
hours. Cell monolayers were washed twice with ice-cold Krebs–
Ringer–HEPES (KRH) (129 mM NaCl, 5 mM NaHCO3, 4.8 mM 
KCl, 1.2 mM KH2PO4, 1 mM CaCl2, 1.2 mM MgCl2, 2.8 mM 
glucose, 10 mM HEPES free acid [pH 7.4]) and then incubated 
with N-hydroxysulfosuccinimide-LC-biotin (Thermo Scientific 
Pierce Protein Research Products, Rockford, IL) (100 µg/mL) for 
2 hours at 4°C. Cells were washed again with KRH and then incu-
bated with KRH containing 10 mM glycine for 15 minutes at 4°C. 
Cell monolayers were washed and lysed, and the lysates were pre-
cipitated with anti-HER2 antibodies. Samples were subjected to 
8% SDS-PAGE gels and analyzed by immunoblotting using 
streptavidin–HRP secondary antibody (Sigma-Aldrich).
For cell fractionation experiments, BT474 cells were cultured 
as above in 100-mm dishes, washed with PBS, incubated in cell 
dissociation buffer (0.25 M sucrose, 1 mM EDTA, 1 mM phenyl-
methyl sulfonyl fluoride, and 10 mM Tris–HCl [pH 7.0]) for 10 
minutes at 37°C. The cell suspension was homogenized on ice 
with a tight-fitting Dounce homogenizer (50 strokes) (Kontes 
Glass Company, Vineland, NJ). This homogenate was centrifuged 
at 4000g for 10 minutes. The resulting pellet was rehomogenized 
(50 strokes) and centrifuged at the same speed. The supernatants 
from these two centrifugation steps were pooled and centrifuged at 
30 000g for 30 minutes. The supernatant was taken as the cytosolic 
fraction and the pellet as the microsomal fraction.
MTT metabolization, Cell Cycle, and Apoptosis Assays
Cell proliferation experiments were carried out using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assays, where MTT is reduced to purple formazan by the 
mitochondria of living cells. Increase in cell number is detected by 
augmented MTT metabolization, and decrease in cell number is 
reflected by decrease in MTT metabolization. BT474, SKBR3, 
MCF7, and T47D cells were plated at a density of 1 × 104 cells per 
well in 24-well plates and cultured overnight in DMEM supple-
mented with 10% FBS. Each well was replaced with 250 µL of 
fresh medium containing MTT (0.5 µg/µL) and incubated for 
1 hour. The medium was then removed and 500 µL of dimethyl 
sulfoxide was added to each well. The plate was agitated in the dark 
for 5 minutes to dissolve the MTT-formazan crystals. The absor-
bance of the samples was recorded at 570 nm in a multiwell plate 
reader (Tecan ULTRA Evolution, Männedorf, Switzerland). The 
first measurement was performed 24 hours after the cells were 
plated and before the addition of the drugs. This value was consid-
ered to be the baseline value. Then, drugs (10 nM trastuzumab, 
1 µM dasatinib, or a combination of 10 nM trastuzumab and 1 µM 
dasatinib) were added to the respective wells, and MTT measure-
ments were performed at 2, 3, and 5 days after treatment. In case 
of dasatinib, we used three doses (0.1, 1, and 10 µM) to plot the 
dose–response curves in all four breast cancer cell lines. The se-
lected doses were one order of magnitude above (10 µM) and 
below (0.1 µM) the dose of dasatinib (1 µM) previously found to be 
effective in triple–negative breast cancer cell lines (17) and also 
spanned the dose range that previously showed inhibition of pro-
liferation in a large panel of cancer cell lines (20). Results were 
plotted as the mean (95% CI) values of quadruplicates from a rep-
resentative experiment that was repeated at least two independent 
times.
For cell cycle analyses, BT474 cells were cultured in 100-mm 
culture dishes, grown to 50%–70% confluence, and treated with 
drugs (10 nM trastuzumab in PBS, 1 µM dasatinib in dimethyl 
sulfoxide [final dimethyl sulfoxide concentration 1:1000], or 
a combination of 10 nM trastuzumab and 1 µM dasatinib) for 
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48 hours. Cell monolayers were then incubated in trypsin–EDTA 
and resuspended in 1 mL of PBS. After three washes with PBS, the 
cell pellets were resuspended in 70% ethanol and incubated for 30 
minutes at 4°C. Cells were centrifuged at 135g, and cell pellets 
were treated with 1 mL of propidium iodide (PI) staining solution 
(PBS containing 50 µg/mL of PI, 0.5% Tween 20, 0.1 µg/mL 
RNase A) (Sigma-Aldrich). DNA content and cell cycle analyses 
were performed by using a FACScalibur flow cytometer and the 
CellQuest software (BD Biosciences).
For apoptosis analyses, BT474 cell monolayers were incubated 
in trypsin–EDTA, washed twice with cold PBS, and then resus-
pended in binding buffer (10 mM HEPES free acid [pH 7.4], 140 
mM NaCl, 2.5 mM CaCl2) at a concentration of 1 × 106 cells per 
mL. A total of 1 × 105 cells were incubated for 15 minutes in the 
dark with Annexin V-fluorescein isothiocyanate (BD Biosciences) and 
PI staining solution (5 µL Annexin V-fluorescein isothiocyanate, 
10 µL of PI [5 µL/mL final concentration], 400 µL binding buffer).
The loss of mitochondrial membrane potential, which is indic-
ative of apoptosis, was evaluated by measuring the fluorescence of 
tetramethylrhodamine ethyl ester (TMRE) dye (Invitrogen). 
TMRE is a cell-permeant fluorescent dye sequestered by the active 
mitochondria and shows reduced staining when mitochondria are 
damaged. Briefly, 2.5 × 105 BT474 cells were plated in 60-mm 
culture dishes, and after 48 hours of treatment with drugs (10 nM 
trastuzumab, 1 µM dasatinib, or a combination of 10 nM trastu-
zumab and 1 µM dasatinib), TMRE (1 µM) was added to the plate 
for 30 minutes. Cells were treated with trypsin–EDTA solution 
and resuspended in 500 µL of PBS before quantitation of fluores-
cence (excitation 488 nm, emission 570 nm) on FACScalibur flow 
cytometer. The data presented as a histogram differentiated 
between cells that preserved TMRE fluorescence (intact mito-
chondria or alive cells) and cells that lost TMRE fluorescence 
(damaged mitochondria or apoptotic cells). The percentage of cells 
that lost the staining is represented as the mean (95% CI) of three 
independent experiments.
To determine whether the combination of trastuzumab and 
dasatinib was synergistic, additive, or antagonist, we used the 
CalcuSyn v2.0 software programme (Biosoft, Ferguson, MO). 
This program allows the calculation of the combination index 
based on the algorithm of Chou and Talalay (27). Combination 
index values less than 1 indicate synergism, values equal to 1 indi-
cate an additive effect, whereas values greater than 1 indicate an-
tagonism. Combination index values from three independent 
experiments were generated. Results were plotted as the mean 
(95% CI) values of duplicates from two independent experiments.
Cell Surface Immunofluorescence
BT474 cells were grown in DMEM with 10% of FBS, and at 80% 
confluence were treated with trypsin–EDTA and seeded on glass 
coverslips. When cells were 30% confluent on the coverslips, they 
were incubated with anti-HER2 antibody for 2 hours at 4°C, 
washed with PBS, and fixed in 2% paraformaldehyde for 30 mi-
nutes at room temperature. Cells were washed twice in PBS and 
thrice in PBS with 0.2% bovine serum albumin for 10 minutes 
each. The cells were then incubated with Cy-3-conjugated sec-
ondary antibodies (1:1000) for 30 minutes and washed thrice in 
PBS with 0.2% bovine serum albumin. Cells were counterstained 
with 4′,6-diamidino-2-phenylindole to detect cell nuclei, and then 
the coverslips were mounted onto microscope slides. Samples were 
analyzed by regular epifluorescence microscopy or by confocal 
immunofluorescence microscopy using a Zeiss LSM 510 Confocal 
Microscope (Carl Zeiss Microimaging, Barcelona, Spain). To 
avoid interference between fluorescence signals, images were cap-
tured using multitracking mode (excitation 480 nm, emission 570 
nm). The intensity maps, generated by quantification of the inten-
sity of each pixel, were obtained using the LSM 510 software as 
previously described (23). The software uses a color-based scale to 
represent the intensities of each pixel (from blue color that repre-
sents the lower intensities to red color that represents the higher 
intensities).
Microarray Analysis of mRNA
BT474 cells were grown in DMEM with 10% of FBS, and when 
80% confluent, cells were treated with drugs (10 nM trastuzumab, 
1 µM dasatinib, or a combination of 10 nM trastuzumab and 1 µM 
dasatinib) for 48 hours. Total RNA was extracted and purified 
using the PureLink Micro-to-Midi kit (Invitrogen). Double-
stranded cDNA and biotinylated cRNA were synthesized using a 
T7-polyT primer and the BioArray RNA labeling kit (Enzo Life 
Sciences, Farmingdale, NY), respectively. The labeled RNA was 
fragmented and hybridized to human oligonucleotide arrays (HU-
133 Plus 2.0) (Affymetrix, Santa Clara, CA) according to the 
manufacturer’s instructions. For the microarray data analysis, 
Affymetrix CEL files from each of the two microarray hybridiza-
tion experiments for the four conditions (untreated control, 10 nM 
trastuzumab, 1 µM dasatinib, and a combination of 10 nM trastu-
zumab and 1 µM dasatinib) were imported into the dChip software 
(Dana Farber Cancer Institute, Boston, MA) (28). Normalization of 
all arrays was done against the array with median overall intensity. 
Genes with low expression values (<100 arbitrary units) were consid-
ered as “absent” and were discarded from the analysis. Genes with 
expression values greater than 100 were analyzed for differential 
expression in pairs of treatment conditions (control vs trastu-
zumab, control vs dasatinib, control vs trastuzumab and dasatinib 
combination, trastuzumab vs dasatinib, trastuzumab vs trastuzumab 
and dasatinib combination, dasatinib vs trastuzumab and dasatinib 
combination). The genes with greater than or equal to twofold 
change in expression (P < .05, Student t test two-sided) were 
studied using the Ingenuity Pathway Analysis software (IPA 8.6; 
Ingenuity Systems Inc., Redwood City, CA). This software allows 
functional grouping of genes according to their participation in 
cellular processes, such as cell cycle regulation, DNA damage, 
adhesion, signaling, and cell metabolism, among many others.
Evaluation of DNA Fragmentation by Comet Assay
Neutral comet assays that detect DNA single- and double-strand 
breaks (DSBs) were performed using a protocol for the single-cell 
gel electrophoresis assay (29). Comet assays are based on the stain-
ing of individual cellular nuclei in cells exposed to an electropho-
retic field. If the nuclear DNA is intact, the image obtained is 
circular. If nuclear DNA suffers breaks, upon exposure to the elec-
tric field the fragmented DNA offers a characteristic “comet” 
appearance of the nuclei, with a head and a trailing tail. The tail 
length is proportional to the DNA damage. For this assay, BT474 
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cells were treated with drugs (10 nM trastuzumab, 1 µM dasatinib, 
or a combination of 10 nM trastuzumab and 1 µM dasatinib) for 48 
hours. After treatment, cells were suspended in 1 mL of 1% low–
melting point agarose (Pronadisa, Madrid, Spain). Microscope 
slides were coated with 100 µL of agarose containing cells and in-
cubated at 4°C in the dark to allow the agarose to solidify. The 
slides were placed inside a 100-mm plate and submerged in lysis 
buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris–HCl [pH 10], 
then 0.01 (vol/vol) Triton X-100 was added overnight). After over-
night lysis of the agarose-embedded cells, the slides were subjected 
to electrophoresis in Tris–borate–EDTA (TBE) buffer (100 mM 
Tris, 100 mM boric acid, 10 mM EDTA, pH 10) for 30 minutes at 
1.5 V/cm. The slides were stained with 80 µL ethidium bromide 
(2 µg/mL) for 5 minutes and then dipped in chilled distilled water 
to remove the excess stain. Finally, the slides were dried and DNA 
was observed at ×40 objective using an Axioplan 2 fluorescence 
microscope (Carl Zeiss Microimaging) equipped with a charge-
coupled device camera. Fifty cells by condition (control, 10 nM 
trastuzumab, 1 µM dasatinib, combination of 10 nM trastuzumab 
and 1 µM dasatinib) were examined. Comet lengths (head plus tail, 
in micrometers) were measured with the OpenLab 5.0 (Florence, 
Italy) software, used to also acquire microphotographs.
Xenograft Studies
Female BALB/c nude mice, 7 weeks old, were obtained from 
Charles River Laboratories (Wilmington, MA). For efficient 
tumor growth, the mice (n = 6 per group) were implanted subcu-
taneously with 1.7 mg, 60-day release, 17b-estradiol pellets 
(Innovative Research, Sarasota, FL). One week later, 1 × 107 
BT474 cells in 200 µL of DMEM and 200 µL of Matrigel were 
injected into the mammary fat pads of mice. Two weeks after the 
injection, mice (n = 6 per group) were randomly assigned into four 
groups (with equal average tumor volumes before initiation of 
treatments)—vehicle, trastuzumab, dasatinib, and drug combina-
tion (trastuzumab and dasatinib combination). The mice were 
treated twice per week with abdominal injection of 600 µg trastu-
zumab in PBS and/or once daily orally with 10 mg/kg dasatinib 
dissolved in 25 mM tartaric acid. Tumor diameters were serially 
measured with a digital caliper (Proinsa, Vitoria, Spain) every 
4 days, and tumor volumes were calculated using the following 
formula: V = (L × W2)/2, where V = volume (cubic millimeters), 
L = length (millimeters), and W = width (millimeters). For bio-
chemical analyses, tumors were resected on day 28 after initiation 
of treatments. The mice were killed by CO2 inhalation, and the 
tumors were resected and frozen in liquid nitrogen. Mice were 
handled at the institute’s (Servicio de Experimentación Animal, 
Salamanca, Spain) animal facility, and all treatments were in accor-
dance with the legal and institutional guidelines.
Statistical Analysis
Comparison of continuous variables between two groups for in 
vitro assays and xenograft tumor model experiments was done 
using a two-sided Student t test. At least two independent experi-
ments were performed for both in vitro and in vivo studies. The 
differences between different drug treatment groups were consid-
ered to be statistically significant when the P values were less than 
.05. Means and 95% confidence intervals are reported, unless in-
dicated otherwise. All data were analyzed using the statistical soft-
ware SPSS 15.0 (SPSS, Inc, Chicago, IL).
Results
Effect of Trastuzumab and Dasatinib Combination on the 
Proliferation of Breast Cancer Cells
To investigate a potential synergistic effect of trastuzumab and 
dasatinib combination on the growth of breast cancer cells, we 
used two cell lines (BT474 and SKBR3) that represent in vitro 
models of HER2 receptor overexpression and activation (23), as 
well as two cell lines (MCF7 and T47D) with normal HER2 
receptor expression (27). We first checked the overexpressed and 
phosphorylated HER2 protein levels (Supplementary Figure 1, 
A and B, respectively, available online) in BT474 and SKBR3 
cells. To determine the right doses of dasatinib for use in com-
bination with trastuzumab, we tested the sensitivity of the breast 
cancer cell lines (BT474, SKBR3, MCF7, and T47D) to dasat-
inib (Supplementary Figure 1, C, available online). The MTT 
metabolization results indicated that 1 µM and lower concentra-
tions of dasatinib could be used for experiments in combination 
with trastuzumab, as these doses inhibited cell proliferation and 
were within the range of clinically achievable concentrations 
(17,20). Previous studies indicated that 10 nM of trastuzumab 
represents an optimal concentration for drug combination 
studies (14).
We next investigated the effect of trastuzumab and dasatinib 
combination on the growth of breast cancer cells (Figure 1, A). In 
BT474 and SKBR3 cell lines, the drug combination had a greater 
inhibitory effect on cell growth compared with treatments with 
single-agent trastuzumab or dasatinib (BT474: trastuzumab vs 
drug combination, mean growth = 93% vs 36%, difference = 57%, 
95% CI = 42.2% to 71.7%, P < .001; dasatinib vs drug combina-
tion, mean growth = 73.5% vs 36%, difference = 37.5%, 95% 
CI = 24.9% to 50%, P < .002; SKBR3: trastuzumab vs drug com-
bination, mean growth = 94.2% vs 37%, difference = 57.2%, 95% 
CI = 50.8% to 63.6%, P < .001; dasatinib vs drug combination, 
mean growth = 66.7% vs 37%, difference = 29.7%, 95% CI = 
21.8% to 37.6%, P < .001) (Figure 1, A). In contrast, in MCF7 and 
T47D cell lines, the drug combination did not show a greater in-
hibitory effect compared with dasatinib alone.
In BT474 cells, dasatinib enhanced the inhibitory effect of 
trastuzumab on cell growth in a dose-responsive manner (Figure 1, 
B). To analyze whether the combined effect was synergistic, we 
used the Chou–Talalay algorithm for combination index analysis 
(27) and found that low doses of dasatinib showed an additive ef-
fect with trastuzumab (0.1 µM dasatinib in combination with 
trastuzumab: combination index = 1.16, 95% CI = 1.05 to 1.27; 
0.25 µM dasatinib in combination with trastuzumab: combination 
index = 1.11, 95% CI = 1.03 to 1.19; 0.5 µM dasatinib in combina-
tion with trastuzumab: combination index = 1.05, 95% CI = 0.96 
to 1.15), whereas 1 µM of dasatinib in combination with trastu-
zumab showed a strong synergistic effect (combination index = 
0.44, 95% CI = 0.30 to 0.58) (Figure 1, C).
Trastuzumab and dasatinib combination also affected the mor-
phology of BT474 cells. In culture dishes, BT474 cells grow as 
monolayers and form island-like clusters. The drug combination 
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Figure 1. Effect of trastuzumab and dasatinib combination on the prolif-
eration of breast cancer cells. A) BT474, SKBR3, MCF7, and T47D cells 
were  cultured  in  the  presence  of  trastuzumab  (10  nM)  or  dasatinib 
(1 µM) or a combination of both drugs, and 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) metabolization was measured. 
Briefly,  cells were  treated with  the  indicated drugs,  and after  3 days, 
MTT  was  added.  Absorbance  was  measured  at  570  nm.  The  mean 
absorbance values of untreated samples from each cell line were taken 
as 100%. Absorbance values of the cells treated with different drugs are 
plotted as percentages with respect to the mean value of the untreated 
samples. Means and 95% confidence intervals of an experiment repre-
sentative of three independent experiments performed in quadruplicate 
are shown. In BT474: *P < .001, trastuzumab vs drug combination; #P = 
.002, dasatinib vs drug combination. In SKBR3: †P < .001, trastuzumab 
vs drug combination; ‡P < .001, dasatinib vs drug combination. Student 
t test (two-sided) was used to compare means between groups and to 
calculate P values. B) Dose–response analysis of dasatinib on the pro-
liferation of BT474  cells  treated with  trastuzumab. Cells were  treated 
with trastuzumab (10 nM) in combination with different doses (0.1, 0.25, 
0.5, or 1 µM) of dasatinib, and MTT metabolization was measured after 
3 days. Control cells were untreated. The results show the means and 
95%  confidence  intervals  of  an  experiment,  performed  two  indepen-
dent  times  in  quadruplicate.  C)  The  combination  index  values  were 
calculated using  the CalcuSyn software. The graph shows  the means 
and  95%  confidence  intervals  of  two  independent  experiments  per-
formed  in  triplicate. D) Effect of  trastuzumab, dasatinib, and  the drug 
combination on the morphology of BT474 cells grown as monolayers 
(top panels) or as three-dimensional (3D) cultures (bottom panels). To 
assess  the  effect  of  different drugs on  the morphology of BT474  cell 
monolayers  (top panels), 5 × 105 cells were plated  in 100-mm dishes, 
allowed  to  adhere  for  24 hours,  then  trastuzumab  (10 nM),  dasatinib 
(1 µM), or a combination of both drugs were added. The images were 
taken after 48 hours. To assess the effect of different drugs on BT474 
cells grown as 3D cultures, 5 × 103 cells were grown in semisolid media 
for  10  days  and  then  treated  with  trastuzumab  (10  nM),  dasatinib 
(1 µM), or a combination of both drugs, for an additional 7 days (bottom 
panels). All images were taken at ×25 magnification. Scale bar = 50 µm. 
E)  Bar  graph  representation  of  the  sphere  diameters  in  3D  cultures. 
BT474  cells  grown  as  3D  cultures  were  treated  with  trastuzumab 
(10 nM), dasatinib (1 µM), or a combination of both drugs. The diameter 
of  the  spherical  cells  (plotted  as  arbitrary  units)  after  treatment with 
drugs  is shown as means and 95% confidence  intervals. Means were 
compared using the Student t test (two-sided). *P < .001, trastuzumab 
vs drug combination; #P < .001, dasatinib vs drug combination.
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caused a contraction of these islands, and the contours of the cells 
were difficult to delineate (Figure 1, D, top panels). We also 
explored whether the trastuzumab and dasatinib combination af-
fected the three-dimensional growth of BT474 cells. For these 
experiments, BT474 cells were cultured in Matrigel, a semisolid 
media in which they form spherical structures. Treatment with the 
drug combination showed a substantial decrease in the diameter of 
these spheres, which was not appreciable when cells were treated 
with the individual agents (trastuzumab vs drug combination, 
mean diameter = 2.85 vs 1.55 arbitrary units, difference = 1.3 arbi-
trary units, 95% CI = .96 to 1.63 arbitrary units, P < .001; dasatinib 
vs drug combination, mean diameter = 2.76 vs 1.55 arbitrary units, 
difference = 1.21 arbitrary units, 95% CI = .82 to 1.59 arbitrary 
units, P < .001) (Figure 1, D, bottom panels, and E).
We also explored whether dasatinib could enhance the action 
of other drugs used in the therapy of breast cancer. Dasatinib did 
not substantially increase the antitumoral effect of gemcitabine in 
BT474 (Supplementary Figure 2, A, available online) and SKBR3 
(Supplementary Figure 2, B, available online) cells. However, 
combination of dasatinib with taxotere or vinorelbine had a higher 
antitumoral effect than treatment with the individual drugs. 
Interestingly, addition of trastuzumab to these combinations 
(dasatinib and gemcitabine, dasatinib and taxotere, dasatinib and 
vinorelbine) showed augmented antitumoral efficacy.
Coordinated Effects of Trastuzumab and Dasatinib on  
HER Signaling
To investigate the mechanism responsible for the biological ac-
tivity of trastuzumab and dasatinib combination, we explored the 
biochemical changes in both single and combined treatments. 
Because trastuzumab and dasatinib inhibit tyrosine kinases (8,21), 
we analyzed their effect on tyrosine phosphorylation in an anti-
body array containing a panel of 42 different RTKs, including the 
ones targeted by these drugs. These experiments showed that the 
most phosphorylated RTKs in BT474 cells corresponded to HER 
receptors, especially HER2 and HER3 (Figure 2, A). Trastuzumab 
decreased the level of phosphorylated HER2, but dasatinib had no 
substantial effect on the amount of phosphorylated HER2. 
However, trastuzumab and dasatinib combination strongly 
decreased phosphorylated HER2 and phosphorylated HER3 
levels. The drug combination showed analogous results in SKBR3 
cells, and both phosphorylated HER2 and phosphorylated HER3 
levels were decreased (Supplementary Figure 3, A, available 
online). Observations were confirmed by immunoprecipitation 
Figure 2. Effect  of  trastuzumab  and  dasatinib 
combination on HER signaling. BT474 cells were 
treated with the indicated drugs (10 nM trastu-
zumab,  1  µM  dasatinib,  or  a  combination  of 
both drugs) for these experiments. A) Cells were 
treated  with  drugs  for  72  hours,  and  lysates 
containing 1 mg protein were analyzed  for  the 
level of  tyrosine phosphorylation of a panel of 
42  receptor  tyrosine  kinases  (RTKs)  using  the 
antibody array-based phosphorylation profiling. 
The  levels  of  phosphorylated  HER2  and  HER3 
are shown (in the lanes indicated by arrows). B) 
Analysis  of  the  epidermal  growth  factor  re-
ceptor  (EGFR)  (or  HER1),  HER2,  and  HER3 
proteins in BT474 cells treated with the respec-
tive drugs for 72 hours. Cell lysates were immu-
noprecipitated  (IP)  with  the  anti-EGFR, 
anti-HER2,  and  anti-HER3  antibodies,  and  im-
munoblots  (IB)  were  performed  with  the  anti-
phosphotyrosine  antibody  (PY).  The  levels  of 
total HER proteins and the corresponding phos-
phorylated levels are shown. Total EGFR levels 
were  analyzed  and  also  used  as  the  loading 
control.  C)  Indirect  immunofluorescence  mi-
croscopy  showing  the  effect  of  drug  combina-
tion on the subcellular localization of HER2 and 
phosphorylated  HER2  (pHER2).  BT474  cells 
were seeded on coverslips and treated with the 
respective drugs  for  48 hours. Cell  surface  ex-
pression of HER2 and pHER2 was analyzed with 
anti-HER2 and anti-pHER2 antibodies and using 
confocal  microscopy.  The  intensity  maps  of 
HER2 and pHER2 were determined using Zeiss 
LSM  510  software.  Reduced  HER2  and  pHER2 
expression was noted after  treatment with  the 
drug combination. D) Effect of drug treatments 
on ERK1 and AKT signaling pathways and cyto-
solic  itinerant  tyrosine  kinases  in  BT474  cells 
treated  with  drugs  for  72  hours.  Cell  lysates 
were analyzed by immunoblotting for the levels 
of different proteins, as well as their phosphory-
lated forms. Total AKT levels were analyzed and 
also used as the loading control. Dasat = dasat-
inib; p = phosphorylated; Trast = trastuzumab.
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and immunoblotting experiments, and it was also observed that 
there was a decrease in the total amount of HER2 and HER3 after 
treatment with the drug combination (Figure 2, B, and 
Supplementary Figure 3, A, available online). The decrease in 
HER2 tyrosine phosphorylation induced by the drug combination 
was also evidenced by immunofluorescence microscopy, and an 
overall decrease in HER2 on the cell surface was also noted 
(Figure 2, C). The latter finding was also substantiated by cell 
surface biotinylation of HER2 proteins (Supplementary Figure 3, 
B, available online). The combined treatment did not substantially 
affect the amount of EGFR, although a small decrease in phos-
phorylated EGFR was detected (Figure 2, B, and Supplementary 
Figure 3, A, available online).
We reasoned that if the combined treatment with trastuzumab 
and dasatinib affected tyrosine phosphorylation of HER receptors, 
the signaling pathways activated by these receptors would conse-
quentially experience an analogous impact. Therefore, we investi-
gated the effect of individual drugs and drug combination on 
RAS-RAF-MEK-ERK1/2 and phosphatidylinositol 3-kinase–
AKT activation pathways, given the important role of these path-
ways in HER signaling. In addition, we also explored the tyrosine 
phosphorylation status of the cytosolic itinerant tyrosine kinases 
c-SRC and FAK, which are well-known dasatinib targets (21). In 
the resting state of phosphorylation, dasatinib inhibited the dual 
phosphorylation of ERK1 and tyrosine phosphorylation of c-SRC 
and FAK (Figure 2, D). The inhibitory effect of trastuzumab and 
dasatinib combination on phosphorylation was analogous to that 
of dasatinib, indicating that the activity of combined drugs on 
these signaling mediators reflect the activity of dasatinib alone. 
Similar to the effect of the drugs on HER receptors, treatment 
with the drug combination inhibited the phosphorylation of the 
adaptor protein SHC1, AKT, as well as a downstream substrate of 
AKT—the 70 kDa S6 protein kinase (p70S6K). Treatment with 
individual drugs did not affect the constitutive resting state phos-
phorylation of these proteins.
Gene Expression Profiling and DNA Damage in Cells 
Treated With Trastuzumab and Dasatinib
In addition to the biochemical studies, we also performed mRNA 
expression profiling of BT474 cells treated with trastuzumab, 
dasatinib, or trastuzumab and dasatinib combination using oligo-
nucleotide arrays. The expression of several genes was altered in 
response to treatment with the single drugs, but more genes 
showed altered expression after trastuzumab and dasatinib combi-
nation treatment (Figure 3, A). Trastuzumab modified the expres-
sion of 181 genes; dasatinib modified the expression of 193 genes; 
and the drug combination modified the expression of 263 genes. 
The expression of some genes was modified only by the drug com-
bination and not by individual drugs (Figure 3, A). The drug com-
bination modified the expression of genes involved in cell cycle 
regulation and DNA recombination and/or repair. Among the 
most notable cell cycle regulators, whose expression was modified 
by the drug combination, were CDK2, cyclin E1, cyclin E2, cyclin 
B1, and p21 (Figure 3, B). The differential expression was statisti-
cally significant for all genes shown in the figure (P < .05). A time-
course analysis of different protein levels demonstrated that the 
level of p21 decreased within 12 hours, CDK2 and cyclin E1/2 
decreased within 36 hours, and cyclin B1 decreased within 24 
hours of treatment with the drug combination (Figure 3, C). In 
contrast, the level of p27, an important negative regulator of cell 
cycle progression in BT474 cells (30), was substantially increased 
by the combined treatment of trastuzumab and dasatinib.
Treatment with the drug combination also modified the ex-
pression of genes that participate in DNA damage responses 
(Figure 3, B). This result led us to explore whether treatment with 
trastuzumab and dasatinib triggered a DNA damage response. Of 
the many types of DNA damage, the most toxic is DNA DSBs 
(31,32). The DNA lesions are repaired mainly through nonhomol-
ogous end joining or homologous recombination (31). Because 
RAD51 recombinase, one of the genes whose expression was mod-
ified by the combined drug treatment, is involved in homologous 
recombination, we first investigated whether the drug combination 
triggered DSBs. Comet assays indicated that treatment of BT474 
cells with the drug combination induced the characteristic “comet” 
appearance of the nuclei, whereas the individual drugs showed no 
such effect (Figure 3, D).
Upon generation of DSBs, the MRE11A–RAD50–NBS1 
(MRN) protein complex is recruited to the sites of the DNA le-
sions, which triggers the activation of kinases such as ataxia telan-
giectasia mutated that phosphorylate several downstream mediators 
(32). One of these downstream molecules is the phosphorylated 
form of histone H2AX (known as gH2AX), which is used as a sur-
rogate marker for the quantitation of DSBs (33). Immunoblot 
results showed that gH2AX was detected in cells treated with 
trastuzumab and dasatinib but not in cells treated with the indi-
vidual drugs (Figure 3, E). A time-course analysis performed to 
define the effects of trastuzumab and dasatinib on proteins that 
participate in the DSB repair pathway verified that the levels of 
RAD1, RAD51, and RAD54B were substantially decreased by the 
drug combination (Figure 3, C), and this decrease coincided with 
the increase in level of gH2AX. The combined drug treatment also 
increased the level of GADD45g, which is involved in the DSB 
repair pathway. The levels of MRE11A and RAD50, both constit-
uents of the MRN complex, were unaffected by trastuzumab and 
dasatinib combination treatment.
Effect of Trastuzumab and Dasatinib Combination on 
Apoptosis
The decrease in MTT metabolization in cells treated with dasat-
inib and trastuzumab could be because of reduced proliferation, 
cell death, or both. Moreover, the genomic and biochemical 
studies indicated deregulation of proteins that control these bio-
logical processes. Therefore, next we investigated the effect of 
different drug treatments on cell cycle and apoptosis. In BT474 
cells, PI staining revealed a pattern of DNA staining, characterized 
by a large G0/G1 peak of interphase cells (2n DNA content), a 
much smaller G2/M peak of cells with duplicated DNA content 
(4n), and an intermediate subpopulation that corresponded to the 
S phase (Figure 4, A). Treatment with the individual drugs did not 
have a substantial effect on the distribution of the different cell 
cycle phases. However, treatment with the drug combination pro-
foundly affected the PI staining of BT474 cells, which impaired 
accurate analyses of the action of the drug combination on the 
different cell cycle phases. We observed that the G0/G1 and 
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G2/M peaks decreased in height, and the relative number of cells in 
the S phase increased. This can be caused by lower sensitivity of 
S phase cells to the action of the drug combination. An important 
accumulation of sub-G0 staining was observed in cells treated with 
the drug combination. As this latter characteristic (ie, accumulation 
of sub-G0 cells) is indicative of cell death (34), we assessed whether 
treatment with trastuzumab and dasatinib combination triggered 
apoptotis in breast cancer cells. Annexin V-fluorescein isothiocya-
nate staining showed that the number of apoptotic cells was elevated 
in BT474 cells treated with the drug combination (trastuzumab and 
Figure 3. Effect of trastuzumab and dasatinib combination on cell cycle 
and DNA damage response. BT474 cells were treated with the indicated 
drugs  (10 nM  trastuzumab,  1 µM dasatinib, or  a  combination of both 
drugs) for these experiments. A) Venn diagram depicting the overlap of 
genes with modified expression levels. B) Colorgram of the expression 
levels of cell cycle and DNA damage genes after 24 hours of treatment 
with the drugs. Control cells were untreated. Red, white, and blue colors 
represent the level of gene expression at greater than mean, mean, and 
lower  than  mean,  respectively.  The  numeric  scale  indicates  the  fold 
change of expression of each gene  in each sample with respect  to  its 
mean expression value across all  samples. The duplicate samples  for 
each drug or drug combination indicate results from two independent 
experiments.  Trast  =  trastuzumab.  Dasat  =  dasatinib.  C)  Immunoblot 
analysis of cells treated with trastuzumab and dasatinib combination for 
the indicated time in hours. The levels of different proteins involved in 
cell  cycle  regulation  and  DNA  damage  are  shown  at  different  time 
points.  Glyceraldehyde-3-phosphate  dehydrogenase  was  used  as  the 
protein loading control. C = control (untreated). D) Comet assay of cells 
treated with different  drugs.  The  images  shown are  representative of 
three  independent  experiments.  The  tail  lengths  of  the  comets  are 
shown in the corresponding bar graph as mean values and 95% confi-
dence intervals. Comparison of means between groups was performed 
using Student t test (two-sided). *P < .001, trastuzumab vs drug combi-
nation; #P < .001, dasatinib vs drug combination. C = control (untreated); 
D = dasatinib; T = trastuzumab; T + D = trastuzumab and dasatinib. E) 
Immunoblot analysis of gH2AX under the conditions described in (D).
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dasatinib combination, 51.4%) compared with cells treated with the 
individual drugs (trastuzumab, 2%; dasatinib, 6.9%) (Figure 4, B).
Apoptosis may be caused by the loss of membrane potential and 
increased permeability of the mitochondrial outer membrane 
(MOM) (35). Analysis of MOM potential indicated that the drug 
combination affected the membrane potential of a greater number 
of cells compared with the individual drugs (control vs drug combi-
nation, mean loss in MOM potential = 18.67 vs 72.67, difference = 54, 
95% CI = 30.04 to 77.95, P = .005; trastuzumab vs drug combination, 
mean loss in MOM potential = 31 vs 72.67, difference = 41.67, 
95% CI = 16.53 to 66.79, P = .019; dasatinib vs drug combination, 
mean loss in MOM potential = 31.67 vs 72.67, difference = 41, 
95% CI = 8.42 to 73.57, P = .032) (Figure 4, C). The results are 
shown as the percentage of cells that lost TMRE staining. Because 
the permeability of MOM is regulated by members of the BCL2 
family, we analyzed the expression levels of BCL2, BCL2L1, and 
MCL1 in cells treated with the individual drugs or the combination. 
The levels of these proteins were not substantially affected after 
treatment with trastuzumab or dasatinib alone; however, the levels 
were almost undetectable after treatment with the drug combina-
tion. In addition, the levels of phosphorylated BAD (a downstream 
target of AKT) and BIRC2 also decreased after treatment with the 
drug combination (Figure 4, D).
To investigate whether a caspase-dependent or independent 
signaling pathway was involved in apoptosis (36), we assessed the 
levels of caspase-3, -8, and -9, on treatment with trastuzumab or 
dasatinib as single drugs, as well as the drug combination (Figure 4, 
E). Treatment with trastuzumab and dasatinib combination showed 
a decrease in the level of all three procaspases. It is noteworthy that 
we were unable to detect the cleaved (active) fragments of these 
caspases in cells treated with the drug combination. However, 
when apoptosis was induced in BT474 cells with tumor necrosis 
factor–related apoptosis-inducing ligand (TRAIL), activation of 
caspases via generation of cleaved fragments was evident (data not 
Figure 4. Effect  of  trastuzumab  and  dasatinib 
combination on cell cycle progression and apo-
ptosis.  BT474  cells were  treated with  the  indi-
cated drugs (10 nM trastuzumab, 1 µM dasatinib, 
or a combination of both drugs) for these exper-
iments. A) Cells were treated with the indicated 
drugs  for 48 hours, and  the cell  cycle progres-
sion  was  examined  by  flow  cytometry  after 
staining with propidium iodide (PI). An increase 
in  the sub-G0 peak and decrease  in  the G0–G1 
and G2–M peaks were noted on treatment with 
the  drug  combination.  The  histograms  of  one 
representative experiment of the three indepen-
dent experiments are shown. B) Flow cytometry 
analysis  of  apoptosis  in  cells  treated  with  the 
indicated  drugs  for  72  hours  and  stained with 
Annexin  V  and  PI.  The  table  shows  the  per-
centage of cells stained with Annexin V and/or 
PI. Means and 95% confidence intervals of three 
independent  experiments  are  shown.  Dasat  = 
dasatinib;  Trast  =  trastuzumab.  C)  Cells  were 
treated  with  the  indicated  drugs  for  48  hours. 
Flow  cytometry  analysis  of  the  mitochondrial 
membrane potential (DΨm) was performed after 
addition  of  1  µM  tetramethylrhodamine  ethyl 
ester dye. Means and 95% confidence intervals 
of  three  independent  experiments  are  shown. 
Student t test (two-sided) was used to compare 
the  mean  loss  in  mitochondrial  membrane 
potential between the groups: †combination vs 
control, P = .005; *combination vs trastuzumab, 
P = .019; #combination vs dasatinib, P = .032. D) 
Cells were  treated with  the  indicated drugs  for 
48  hours,  and  immunoblot  analysis  was  done 
for antiapoptotic  (BCL2, BCL2L1, BIRC2, MCL1) 
and  proapoptotic  (BAD)  proteins.  C  =  control 
(untreated); D = dasatinib;  T  =  trastuzumab. E) 
Immunoblot  analysis  of  caspase-3,  -8,  and  -9 
under  the  same  experimental  conditions  as  in 
(D).  F)  Effect  of  caspase  inhibitors  on  cells 
treated with  the  drug  combination.  Cells were 
treated with drugs and caspase inhibitors, either 
individually,  or  simultaneously,  as  indicated  in 
the  figure.  The  following  concentrations  were 
used: TRAIL  (1 nM, combined with 1 µg/mL of 
cycloheximide to increase the activity of TRAIL), 
caspase-8 inhibitor (Z-IETD-FMK, 1 µM), caspase 
9 inhibitor (Z-LEHD-FMK, 1 µM), and pancaspase 
inhibitor (Z-VAD-FMK, 1 µM). The cells were stained with Annexin V and 
analyzed  by  flow  cytometry.  The bar graph  represents  the mean  per-
centage of Annexin V-positive cells from three independent experiments. 
Ninety-five  percent  confidence  intervals  are  also  shown.  Control  cells 
were untreated. Dasat = dasatinib; TRAIL = tumor necrosis factor–related 
apoptosis-inducing ligand; Trast = trastuzumab.
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shown). Furthermore, we used caspase inhibitors to preclude the 
possibility that caspases were involved in the drug combination–
induced apoptosis. Inhibitors of caspase-8 (Z-IETD-FMK), cas-
pase-9 (Z-LEHD-FMK), or a pancaspase inhibitor (Z-VAD-FMK) 
did not affect the drug combination–induced apoptosis (Figure 4, 
F). In contrast, the pancaspase inhibitor showed near complete in-
hibition of TRAIL-induced cell death.
Taken together, these data indicated that although treatment 
with drug combination decreased the caspase levels, it did not 
induce their activation, and apoptosis was likely triggered by cas-
pase-independent pathways. One of the caspase-independent 
pathways that may provoke cell death is caused by release of the 
apoptosis-inducing factor NAIF1 from the mitochondria (35). 
NAIF1 is a ubiquitously expressed flavoprotein that is normally 
localized to the mitochondrial intermembrane space. Increases in 
MOM permeability caused by apoptotic stimuli cause release of 
NAIF1 to the cytosol that then moves to the nucleus where it fa-
cilitates apoptotic responses, such as nuclear condensation (36). 
Treatment of BT474 cells with trastuzumab and dasatinib combi-
nation showed release of NAIF1 to the cytosolic compartment 
(Supplementary Figure 3, C, available online).
Efficacy of Trastuzumab and Dasatinib Combination on 
Tumor Growth In Vivo
To determine whether the synergistic action of the drug combina-
tion was also observed in vivo, we implanted BT474 cells into the 
mammary fat pad of mice randomly assigned to the following four 
groups—untreated control, dasatinib, trastuzumab, or a combina-
tion of trastuzumab and dasatinib. The tumors continued to grow 
in the untreated group (Figure 5, A), and by day 28 of follow-up, 
the mice were killed because of the large size of their tumors. In 
agreement with the in vitro results, the combination of trastu-
zumab and dasatinib showed a superior antitumoral effect com-
pared with either drug alone (control vs combination, mean 
volume = 2.6 vs 0.5 cm3, difference = 2.1 cm3, 95% CI = 0.76 
to 3.51 cm3, P = .010; trastuzumab vs combination, mean tumor 
volume = 1.5 vs 0.5 cm3, difference = 1.0 cm3, 95% CI = 0.12 to 1.93 
cm3, P = .032; dasatinib vs combination, mean volume = 1.48 vs 0.5 
cm3, difference 0.98 cm3, 95% CI = 0.50 to 1.45 cm3, P = .003) 
(Figure 5, B). It is noteworthy that the tumors from mice treated 
with the drug combination showed regression, whereas tumors 
from mice treated with the individual drugs showed stability in size 
or slight growth (Figure 5, A and B). Because of the strong antitu-
moral effect of the drug combination, we decided to maintain two 
mice from this group to follow the evolution of the tumors. In 
these mice, treatment with trastuzumab and dasatinib combination 
resulted in complete regression of the tumors by day 36, and the 
tumors did not relapse at the site of injection even after discontin-
uation of the treatment for a long period of time (Figure 5, C).
Tumor samples were also analyzed for the phosphorylation 
levels of HER receptors, as well as the levels of DNA damage 
response proteins. The combined drug treatment showed a 
decrease in the level of phosphorylated HER2 compared with 
control mice or mice treated with the individual drugs (Figure 5, 
D). The combined drug treatment also showed a decrease in the 
levels of RAD1, RAD51, RAD54B, and an increase in the level of 
gH2AX (Figure 5, E).
Discussion
In this study, we showed that the combination of trastuzumab with 
dasatinib was highly effective against breast cancer cells overex-
pressing HER2 receptors. Both drugs individually inhibited cell 
proliferation in vitro and exhibited antitumoral action, but their 
combination showed a more potent effect on HER2-overexpressing 
cells. However, compared with single drugs, treatment with the 
drug combination did not show a greater inhibition of prolifera-
tion in cells with normal expression of HER2 receptors. We con-
firmed these observations in vivo in a mouse mammary fat pad 
model of breast cancer. Treatment of tumor-bearing mice with the 
drug combination showed a stronger inhibitory effect on tumor 
growth than treatment with single drugs. We further demon-
strated that there was a complete regression of tumors, even large 
tumors, in mice treated with the drug combination. In addition, 
discontinuation of the treatment for 9 months did not result in 
tumor recurrence.
The mechanistic studies indicated that the drug combination 
strongly decreased the levels of phosphorylated HER2 and phos-
phorylated HER3, which were accompanied by a decrease in the 
total amount of these receptors. We explored whether the com-
bined treatment affected the downstream signaling routes, such as 
the ERK1 or AKT pathways that regulate cell proliferation and 
survival (37,38). Dasatinib had the same inhibitory effect on the 
phosphorylated levels of ERK1 as the combined drug treatment. 
Therefore, the exclusive inhibition of ERK1 cannot explain the 
effects of the combined drug treatment on cell proliferation and 
cell death. Analogously, treatment with dasatinib inhibited SRC or 
FAK phosphorylation to the same degree as the combined drug 
treatment. These two kinases are known targets of dasatinib (21) 
and have been reported to participate in several oncogenic pro-
cesses (39). We noted that the combined treatment, but not the 
individual drugs, decreased the level of phosphorylated AKT. 
Downstream targets of AKT such as p70S6K and BAD were also 
affected by the combined drug treatment, but not by the individual 
drugs, as the resting phosphorylated levels of these proteins were 
reduced on treatment with trastuzumab and dasatinib. The inhibi-
tion of different signaling pathways suggests that the synergistic 
antitumoral action of the combined drug treatment may result 
from the sum of the inhibition of multiple signaling routes 
involved in the control of cell proliferation and survival.
Our results showed that the drug combination also affected 
important regulators of cell cycle progression and a group of 
proteins involved in DNA repair and/or recombination. Moreover, 
the drug combination induced DNA DSBs and a DNA damage 
response that was evidenced by the phosphorylation of H2AX 
protein. DNA damage can induce cell cycle arrest through activa-
tion of kinases such as ataxia telangiectasia mutated (ATM), ataxia 
telangiectasia and RAD3-related kinase (ATR), and the CHK 
checkpoint homolog 1 or 2 kinases (CHEK1 or CHEK2, respec-
tively) that reduce CDK activity by various mechanisms (32). The 
decrease in CDK activity may provoke arrest of cell cycle progres-
sion at the G1–S or G2–M checkpoints, which are thought to 
increase the time available for DNA repair.
The drug combination also induced caspase-independent apo-
ptosis. This was supported by the lack of any effect of the caspase 
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inhibitors on apoptosis induced by the drug combination. One of 
the possible mediators in caspase-independent apoptosis is NAIF1, 
a protein that is released from the mitochondrial intermembrane 
space by certain apoptotic stimuli. The release of NAIF1 from 
the mitochondria to the cytosol, on treatment with the drug com-
bination, indicated that this mechanism could be responsible for 
caspase-independent apoptosis.
The fact that the drug combination severely affected the DNA 
repair machinery and led to the accumulation of DSBs raises some 
questions regarding the mechanism of control of DNA repair 
machinery by tyrosine kinases and the potential clinical implica-
tions. The time-course studies showed a decrease in the level of 
RAD51 protein, sequentially followed by an accumulation of 
gH2AX protein. It is possible that the decrease in the level 
of RAD51 protein impedes adequate repair of spontaneous DNA 
lesions, and accumulation of such lesions triggers a DNA damage 
response that results in apoptosis. If that is the case, it is possible 
that the integrity of the homologous recombination machinery is 
critically controlled by the interplay of tyrosine kinases sensitive 
to trastuzumab and dasatinib. In support of our hypothesis, a 
recent report showed that erlotinib, an inhibitor of EGFR, 
blocked homologous recombination repair of the DSBs in breast 
cancer cells through reduction of RAD51 foci formation (40). 
Previous studies have also indicated that RTKs may regulate 
DNA repair (41,42). Gefitinib, another EGFR inhibitor, was 
shown to impede DNA repair in response to ionizing radiations 
in macrocytic lung cancer cells (41). The mutated forms of MET 
protein, an RTK implicated in several oncogenic processes such 
as invasion and metastasis (43) or drug resistance (44), have been 
reported to bind to and phosphorylate RAD51, facilitating DNA 
repair in tumor cells (42). Recently, the Williams–Beuren 
syndrome transcription factor (WSTF; also known as BAZ1B), a 
tyrosine kinase that is a component of the WICH complex 
(WSTF-ISWI ATP-dependent chromatin-remodeling complex), 
has been shown to regulate the DNA damage response through 
phosphorylation of Tyr142 of H2AX (45).
From the clinical point of view, the fact that trastuzumab and 
dasatinib combination induced DNA damage in HER2-
overexpressing cells in this study, opens up the possibility of com-
bining these drugs in the treatment of HER2-positive breast cancers. 
In this context, we showed that dasatinib may enhance the activity of 
treatments for breast cancer that are currently used in the clinics to 
Figure 5. Effect of trastuzumab and dasatinib com-
bination  on  tumor  development  in  vivo,  HER2 
phosphorylation,  and  levels  of  DNA  damage 
response  proteins. A)  We  injected  1  ×  107  BT474 
cells  into  the mammary  fat pad of  female BALB/c 
nude  mice.  After  2  weeks,  mice  were  either  left 
untreated  (control,  n  =  6)  or  treated  with  trastu-
zumab (T) and dasatinib (D) combination (T + D, n 
= 6; 600 µg trastuzumab injected abdominally twice 
a week and once daily orally with 10 mg/kg dasat-
inib). Tumor growth in representative mouse from 
control and treated groups on day 28 is shown; the 
arrow indicates the position of the tumor. B) Tumor 
sizes of control mice (n = 6) and those treated with 
trastuzumab, dasatinib, or the drug combination (n 
= 6 per group) at  the same doses as  in  (A) at  the 
end of the treatment (day 28). Control vs drug com-
bination, †P = .010; trastuzumab vs drug combina-
tion, *P = .032; dasatinib vs drug combination, #P = 
.003. P values were calculated using Student t test 
(two-sided). C) Effect of drug combination on large 
and small tumors from two mice that showed com-
plete  regression  of  the  tumors  on  day  36  after 
treatment. The data plotted correspond to the mea-
surements  of  tumors  from  two  different mice. D) 
Dot blot analysis showing the levels of phosphory-
lated HER proteins in the tumor xenografts. Control 
PY  =  extracts  of  BT474  cells  with  high  levels  of 
tyrosine-phosphorylated  proteins.  E)  Immunoblot 
analysis  of  proteins  involved  in  DNA  damage 
response  in the tumor xenografts. Tumors from a 
control mouse and a mouse treated with the drug 
combination  were  analyzed.  Tumors  from  two 
mice for each condition were tested. Representative 
immunoblot is shown.
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treat HER2-positive patients. In addition, our results also offer the 
interesting option of using dasatinib with other antineoplastic agents 
in tumors that may be particularly sensitive to DNA damaging drugs 
or radiotherapy. Interestingly, in head and neck cancer, a radiosen-
sitive tumor, in vitro studies have shown antitumoral activity of 
agents that target SRC combined with gefitinib (22). Also, the effec-
tiveness of anti-EGFR therapies in colon cancer opens the possibility 
of exploring whether dasatinib synergizes with anti-HER drugs or 
radiotherapeutic treatments in these pathologies.
Our study may have a few limitations. Although, the promising 
findings of this preclinical study indicate potential clinical benefits, 
we cannot predict the effectiveness or toxicity of the drug combina-
tion in humans. Of note, analysis of the antiproliferative effect of the 
drug combination using the Chou–Talalay algorithm indicated that 
the lower doses of dasatinib (0.1, 0.25, and 0.5 µM) were additive to 
trastuzumab, whereas the dose of 1 µM showed synergistic effect. 
The latter is an achievable concentration (20), but the fact that the 
synergistic effect was observed at a high concentration of dasatinib 
should be taken into account for the adequate design of clinical trials.
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